Last edition
News about "CNS drug development "
TG Therapeutics Launches Phase 2 Trial of BRIUMVI for Schizophrenia
TG Therapeutics has initiated a Phase 2 trial of BRIUMVI in treatment-resistant schizophrenia, evaluating B-cell depletion as a potential therapy for patients with immune dysfunction.
CNS Drug Development | 07/07/2026 | By News Bureau
Insilico Medicine and SK Biopharmaceuticals have entered an Artificial Intelligence (AI)-powered drug discovery collaboration worth up to USD 2.5 billion to develop innovative therapies for neuroimmune disorders.
CNS Drug Development | 23/06/2026 | By News Bureau | 292
Suven Life Sciences will showcase its differentiated CNS clinical portfolio at BIO International Convention 2026, featuring late-stage drug candidates for Alzheimer’s agitation, Major Depressive Disorder (MDD), narcolepsy, Parkinson’s-related cognitive impairment, and other CNS disorders.
CNS Drug Development | 22/06/2026 | By News Bureau | 118
Trevi Therapeutics Welcomes James V. Cassella as Chief Development Officer
Jim will play an integral role in progressing Haduvio by utilizing his broad drug development experience and his proven hands-on leadership of scientific and regulatory teams through drug approvals.
CNS Drug Development | 01/10/2024 | By Aishwarya | 555
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy